Drugs Made In America Acquisition II Corp. DMII
$10.16
-$0.01-0.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 09/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 194.49% | 72.01% | -- | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 194.49% | 72.01% | -- | ||
| Operating Income | -194.49% | -72.01% | -- | ||
| Income Before Tax | 11,639.37% | 7,415.01% | -- | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 11,639.37% | 7,415.01% | -- | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 11,639.37% | 7,415.01% | -- | ||
| EBIT | -194.49% | -72.01% | -- | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | 2,400.00% | 1,548.94% | -- | ||
| Normalized Basic EPS | 2,368.42% | 1,520.00% | -- | ||
| EPS Diluted | 2,400.00% | 1,548.94% | -- | ||
| Normalized Diluted EPS | 2,368.42% | 1,520.00% | -- | ||
| Average Basic Shares Outstanding | 409.60% | 409.60% | -- | ||
| Average Diluted Shares Outstanding | 409.60% | 409.60% | -- | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||